TY - JOUR
T1 - National trends of Laser interstitial thermal therapy (LITT) and Vagus Nerve stimulation (VNS) for refractory epilepsy in adult patients
T2 - A Nationwide Inpatient Sample based propensity score matched analysis
AU - Sharma, Mayur
AU - Scott, Victoria
AU - Ugiliweneza, Beatrice
AU - Wang, Dengzhi
AU - Boakye, Maxwell
AU - Neimat, Joseph
AU - Sreenivasan, Sanjeev
N1 - Publisher Copyright:
© 2024 Elsevier Ltd
PY - 2025/1
Y1 - 2025/1
N2 - Objective: The aim of our study was to report the national trends of Vagus nerve stimulation (VNS) and Laser interstitial thermal therapy (LITT) and compare their outcomes in patients with medically refractory epilepsy (RE). Methods: Nationwide Inpatient Sample database (NIS, 1998–2018) was used to extract the data using the ICD-9/10 codes. Adult patients (>18 years) with a primary diagnosis of RE who underwent either VNS or LITT were included. Patient demographics, complications, length of hospital stay (LOS), discharge disposition and index-hospitalization costs were analyzed. Results: A cohort of 226,248 patients with RE were included, of which only 0.66 % underwent VNS (n = 1500) and 0.34 % (n = 770) underwent LITT. VNS accounted for 66 % of the surgical procedures. The use of LITT gradually increased from 2012 (0.69/1000 RE cases) to 2018 (4.43/1000 RE cases) compared to VNS (2012: 9.85/1000 RE to 2018: 5.31/1000 RE cases). Median age was similar across the cohorts (LITT: 38 years; VNS: 36 years, p = 0.33). Index hospitalization median charges were significantly lower following LITT compared to VNS (LITT: $ 115,838; VNS: $ 131,984, p < 0.0033). No differences in terms of median LOS, discharge to home, complications and median index hospitalization charges were noted between the procedures (LITT vs. VNS). Conclusion: LITT is increasingly being performed for RE with decreasing trends for VNS. The complications profile was similar among both the procedures. Both LITT and VNS are minimally invasive and safe treatment modalities in carefully selected patients with RE.
AB - Objective: The aim of our study was to report the national trends of Vagus nerve stimulation (VNS) and Laser interstitial thermal therapy (LITT) and compare their outcomes in patients with medically refractory epilepsy (RE). Methods: Nationwide Inpatient Sample database (NIS, 1998–2018) was used to extract the data using the ICD-9/10 codes. Adult patients (>18 years) with a primary diagnosis of RE who underwent either VNS or LITT were included. Patient demographics, complications, length of hospital stay (LOS), discharge disposition and index-hospitalization costs were analyzed. Results: A cohort of 226,248 patients with RE were included, of which only 0.66 % underwent VNS (n = 1500) and 0.34 % (n = 770) underwent LITT. VNS accounted for 66 % of the surgical procedures. The use of LITT gradually increased from 2012 (0.69/1000 RE cases) to 2018 (4.43/1000 RE cases) compared to VNS (2012: 9.85/1000 RE to 2018: 5.31/1000 RE cases). Median age was similar across the cohorts (LITT: 38 years; VNS: 36 years, p = 0.33). Index hospitalization median charges were significantly lower following LITT compared to VNS (LITT: $ 115,838; VNS: $ 131,984, p < 0.0033). No differences in terms of median LOS, discharge to home, complications and median index hospitalization charges were noted between the procedures (LITT vs. VNS). Conclusion: LITT is increasingly being performed for RE with decreasing trends for VNS. The complications profile was similar among both the procedures. Both LITT and VNS are minimally invasive and safe treatment modalities in carefully selected patients with RE.
KW - LITT
KW - National trends
KW - Nationwide inpatient sample
KW - Outcomes
KW - Refractory epilepsy
KW - VNS
UR - https://www.scopus.com/pages/publications/85210020581
UR - https://www.scopus.com/pages/publications/85210020581#tab=citedBy
U2 - 10.1016/j.jocn.2024.110932
DO - 10.1016/j.jocn.2024.110932
M3 - Article
C2 - 39591697
AN - SCOPUS:85210020581
SN - 0967-5868
VL - 131
JO - Journal of Clinical Neuroscience
JF - Journal of Clinical Neuroscience
M1 - 110932
ER -